Technology Council of Maryland (TCM) membership met with Congressman Steny Hoyer in an event sponsored by TCM Government Relations Committee members, University of Maryland and Venable, LLP. As Majority Leader, the number two position in the US House of Representatives, Congressman Hoyer provided a briefing on what technology issues are important to congressional leadership. Afterward, TCM members had the opportunity to discuss with Majority Leader Hoyer what issues are impacting their businesses.
On September 27th, TCM was able to secure an exclusive lunch meeting with the Maryland Congressional Delegation. The Delegation’s lunch featured brief presentations from TCM leadership about issues important to technology and biotechnology companies. The meeting was attended by Julie Coons (TCM CEO), Ed Rudnic (TCM Chairman), John Nyland (TCM Past Chairman), Larry Letow (TCM Tech Alliance Chairman), Steve Trevisan (TCM MdBio Chairman) and Jerry Parrott (TCM Board member and Government Relations Committee Chairman). Among the issues discussed were SBIR funding, the Research and Development Tax Credit, government contracting and workforce issues as well as federal funding priorities such as NIST, FDA and NIH. Several members of the Delegation attended the meeting including Congressmen Steny Hoyer, Chris Van Hollen, Al Wynn, Roscoe Bartlett and Dutch Ruppersberger.
Mr. Trevisan, President and CEO of Rockville-based Accelovance, serves as Chairman of TCM/MdBio; a not-for-profit trade association dedicated to serving the needs of Maryland’s technology-based industries. He is no stranger to local biotech endeavors in Maryland, having started several successful drug development research organizations.
Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique system for delivering quality, on time, and cost effective clinical studies. Accelovance offers CRO services, clinical sites and a dedicated patient recruitment department with call center. In China, the Company operates through its wholly-owned foreign enterprise in Beijing as a (CRO). Accelovance is focused on optimizing the quality and productivity of multiple clinical sites, through strong central management and targeted pro-active patient recruitment. Delivering high quality and timely clinical trial support services, Accelovance is committed to understanding and meeting its clients needs to contribute to their success.
For more information, visit the company’s website at http://www.accelovance.com.
CONTACT: Media: Garrett D. Smith at 240.238.4900